KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2025)

Amneal Pharmaceuticals has reported Non Operating Income over the past 9 years, most recently at -$56.8 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$56.8 million for Q4 2025, up 81.91% from a year ago — trailing twelve months through Dec 2025 was -$114.7 million (up 70.11% YoY), and the annual figure for FY2025 was -$254.9 million, up 16.25%.
  • Non Operating Income for Q4 2025 was -$56.8 million at Amneal Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Over the last five years, Non Operating Income for AMRX hit a ceiling of $128.0 million in Q4 2022 and a floor of -$313.9 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was $1.2 million (2024), compared with a mean of -$33.8 million.
  • Peak annual rise in Non Operating Income hit 1829.38% in 2022, while the deepest fall reached 946.06% in 2022.
  • Amneal Pharmaceuticals' Non Operating Income stood at $6.6 million in 2021, then soared by 1829.38% to $128.0 million in 2022, then tumbled by 296.33% to -$251.3 million in 2023, then dropped by 24.95% to -$313.9 million in 2024, then soared by 81.91% to -$56.8 million in 2025.
  • The last three reported values for Non Operating Income were -$56.8 million (Q4 2025), $1.2 million (Q3 2025), and -$59.7 million (Q2 2025) per Business Quant data.